Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Published bySerafino Cocco Modified over 5 years ago

Similar presentations

Presentation on theme: "Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,"— Presentation transcript:

1 Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba, MD, PhD, Jana Bobokova, MD, Antonio Calles, MD, Rafael Álvarez, MD, Eugenio Cuadrado, MD, Aranzazu Manzano, MD, Eduardo Díaz-Rubio, MD, PhD  Journal of Thoracic Oncology  Volume 4, Issue 7, Pages (July 2009) DOI: /JTO.0b013e3181a4b8fb Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier survival estimates for a group of patients with stage IA disease from the Duke, ACOSOG, and CALGB cohorts and the subgroups predicted to have either a high probability (>0.5) or a low probability (≤0.5) of recurrence by the application of the Lung Metagene Model. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier estimates of overall survival and relapse-free survival for the 101 patients with NSCLC (Panel A and Panel B, respectively) and for the 59 patients with stage I or stage II disease (Panel C and Panel D, respectively), according to the Five-Gene Signature. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier estimates of disease-free survival (A) and overall survival (B) among patients with stage I NSCLC according to ERCC1 and RRM1 expression levels. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Event-free and median survival according to expression of TRX (A and C) and BRCA1 (B and D). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 A, Relapse-free survival and overall survival curves for low-tubulin expressors according to treatment assignment; B, Relapse-free survival and overall survival curves for high-tubulin expressors according to treatment assignment. vin/cisp, vinorelbine/cisplatin. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Overall survival curves of patients with p53 protein expression (immunohistochemistry) results. (A) p53 IHC results known; (B) p53 IHC results, observation; (C) p53 IHC positive; and (D) p53 IHC negative. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

8 FIGURE 7 Odds ratios for recurrence among case patients when compared with controls, according to methylated gene and site. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,"

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes  Ruben Pio, PharmD, PhD, Jackeline.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes  Ruben Pio, PharmD, PhD, Jackeline.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation  Jean-Yves.

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation  Jean-Yves.

Similar presentations

Ads by Google